Leaps by Bayer

Venture capital firm

Recent changes

  1. Jul 2, 2026Invested in Celea Therapeutics ($180M) Celea Therapeutics

Portfolio

1 total
Celea Therapeutics

Recent Investment Activity

1
DateCompanyEventAmountValuationInvestorsSource
Jul 2, 2026Celea Therapeuticsfunding round$180M—
RA CapitalLeaps by BayerPureTech Health
outlined = lead
Celea Therapeutics

Co-Investors

2
PureTech Health · 1 sharedRA Capital · 1 shared

Latest Pulse

Pulse coverage →
  1. Celea Therapeutics Raises $180M Series B for Pulmonary Fibrosis DrugCelea Therapeutics, a clinical-stage biotech spun out of PureTech developing deupirfenidone for idiopathic pulmonary fibrosis, announced a $180 million Series B on July 2, led by RA Capital and Leaps by Bayer, with PureTech and additional unnamed.→
Sources & methodologyshow
Where these figures come from

Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.

How we verify data · Suggest a correction